laboratori corpor
remain bullish lh follow result mark solid core lab trend
strong cro growth robust cash flow despit on-going head wind lab
 pama contract expect pama pressur persist
non-renew beaconlb also impact continu
like complementari biz model view larg independ uniqu
posit lab space expect on-going cost saving/effici initi
help off-set head wind see meaning opportun capit deploy
reiter buy rate pt ep
covanc valu prop reson covanc post anoth strong total
fx head wind bp bp oper margin expans
addit ttm net-book-to-bil grew net order
backlog exit expect convert next
month lh see encourag traction custom evidenc
win studi major custom recent
 center open shanghai view china anoth intrigu potenti
sourc growth continu view scope integr capabl
geograph footprint covanc offer uniqu expect
complement on-going invest integr envigo
net synergi end final launchpad initi remain
track run rate save expect end
strateg posit enviabl lh diagnost busi continu
face headwind pama manag care contract result solid
segment revenu slightli ahead estim
volum vs strhe revenue per req vs strhe
came better think despit pama pressur bp organ
compani also announc buy
opt renew beaconlb pilot florida result bp hit
rev/req compani expect impact roughli bp
despit near-term head wind continu view labcorp superbl
posit long-term winner given compani scale sophist
low-cost/high qualiti offer world shift toward valu also
expect a/shar gain opportun acceler pama price pressur
weigh smaller provid payor increasingli look shift volum
tr target
laboratori corpor america hold
focu consum centric effort remain high part on-going consum focu lh
continu expand retail footprint labcorp walgreen hold locat
open state addit locat progress expect continu
view lh inclus find platform potenti increment driver see
opportun leverag combin platform non-lab servic time cro recruit
chronic care manag well hub compani also seen encourag respons
pixel labcorp product recent expand menu test packag addit
offer ad month
in-lin result net revenu bit ahead estim modestli
better expect lab revenu vs strhe off-set slightli lower covanc revenu
vs strhe cost roughli in-lin gross margin ahead
think sg bit heavier vs strhe higher personnel cost
merit increas addit payrol day kept operaitng result in-lin bottom line benefit
lower tax rate result adjust ep two cent ahead estim
estim reflect beacon flow trend remain strong cffo
come ahead estim manag reiter full
year guidanc lh spent bought back
stock exit cash debt debt-to-ltm ebitda ratio
manag also narrow full year adjust ep guidanc rang prior
 includ overal revenu growth prior
lab revenu prior covanc revenu growth
prior tweak estim reflect updat
guidanc non-renew beacon lb contract revis revenu estim stand
reflect lower assum yoy growth
lab busi vs prior tie beacon adjust ep
reiter buy rate price target
page
laboratori corpor america hold
laboratori corpor america mm
servic
revenu
incom equiti invest
revenu
page
laboratori corpor america hold
headquart burlington nc laboratori corpor america hold labcorp one
largest independ clinic laboratori broad offer includ routin test
blood chemistri urinalys pap hiv substance-abus etc specialti test oncolog hiv
genotyp phenotyp diagnost genet clinic research trial compani also
oper cro busi extend servic offer includ clinic research provid
meaning intern presenc chiltern acquisit meanin expand cro servic
clinic lab remain integr part healthcar deliveri model diagnost test critic
compon treatment decis process combin covanc busi lh boast
signific scale divers servic offer uniqu posit area person medicin
potenti risk-bas reimburs system diversifi revenu stream custom
base also meaning lower reimburs risk one custom repres revenu
govern pay manag addit signific clinic horsepow geograph
diversif provid platform addit growth opportun time rate share buy
valuat risk
price target base stock trade adjust ep premium
current multipl given labcorp sizabl esoter presenc solid cash flow gener attract
cross-sel opportun covance/chiltern view appropri addit believ
effici initi aggress focu cost control could provid support
risk rate price target includ advers shift reimburs pama poor integr
acquisit pressur econom uncertainti perform covanc increas
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
